(Q24202873)

5

object named as

Sally N Merry

0 references

author name string

Sarah E Hetrick

1

0 references

Georgina R Cox

3

0 references

Magenta B Simmons

Cochrane Database of Systematic Reviews

4

0 references

publication date

14 November 2012

0 references

published in

0 references

cites work

An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Fluoxetine in child and adolescent depression: acute and maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

The Kutcher Adolescent Depression Scale: assessment of its evaluative properties over the course of an 8-week pediatric pharmacotherapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Paroxetine in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Treatment for Adolescents with Depression Study (TADS): safety results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Treatment for Adolescents With Depression Study (TADS): Rationale, Design, and Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Withdrawal of attention rather than pharmacological treatment affects suicide rates in depressed children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

The cost of dichotomising continuous variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Suicidal attempts among older adolescents: prevalence and co-occurrence with psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Childhood and adolescent depression. II: Research in clinical populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Relation between anxiety and depressive disorders in childhood and adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Childhood and adolescent depression: a review of the past 10 years. Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Psychopathology and its relationship to suicidal ideation in childhood and adolescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Psychiatric risk factors for adolescent suicide: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Clinical practice. Adolescent depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Antidepressants and pediatric depression--the risk of doing nothing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Diagnosis and measurement of adolescent depression: a review of commonly utilized instruments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Phenomenology of major depression from childhood through adulthood: analysis of three studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

The assessment of affective disorders in children and adolescents by semistructured interview. Test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Review of the efficacy and safety of antidepressants in youth depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Reboxetine versus other antidepressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Fluoxetine versus other types of pharmacotherapy for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Paroxetine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Venlafaxine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Escitalopram versus other antidepressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Sertraline versus other antidepressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Pharmacological treatment of adolescent major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Why are we not getting any closer to preventing suicide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Survey of investigators' opinions on the acceptability of interactions with patients participating in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Recent developments and current controversies in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Psychiatric symptoms and their relationship to suicidal ideation in a high-risk adolescent community sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Incidence of major depressive disorder and dysthymia in young adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

A meta-analysis of the effects of cognitive therapy in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Forum: the use of selective serotonin reuptake inhibitors in depressed children and adolescents: commentary on the meta-analysis by Hetrick et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Agomelatine versus other antidepressive agents for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Antidepressants and suicide: what is the balance of benefit and harm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Suicidality in pediatric patients treated with antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Adult outcomes of childhood and adolescent depression. I. Psychiatric status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Tricyclic drugs for depression in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Are selective serotonin reuptake inhibitors a risk factor for adolescent suicide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

The use of SSRIs in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Imputation methods for missing outcome data in meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Citalopram versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

The increased use of antidepressants has contributed to the worldwide reduction in suicide rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Antidepressants and the risk of suicidal behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Efficacy and safety of antidepressants for children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Are child-, adolescent-, and adult-onset depression one and the same disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Power and sample size determination when assessing the clinical relevance of trial results by 'responder analyses'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Depressive disorders in childhood. I. A longitudinal prospective study of characteristics and recovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Depressive disorders in childhood. IV. A longitudinal study of comorbidity with and risk for anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Depressive disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Active placebos versus antidepressants for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Ten-year review of rating scales. II: Scales for internalizing disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Milnacipran versus other antidepressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

A black-box warning for antidepressants in children?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Duloxetine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Relationship Between Antidepressant Medication Treatment and Suicide in Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Fluvoxamine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Unipolar depression in adolescents: clinical outcome in adulthood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

National suicide rates 1961-2003: further analysis of nordic data for suicide, autopsies and ill-defined death rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

The treatment of adolescent depression in the era of the black box warning

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Do antidepressants reduce suicide rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

The mental health of young people in Australia: key findings from the child and adolescent component of the national survey of mental health and well-being

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Global assessment of psychosocial functioning in child and adolescent psychiatry. A review of three unidimensional scales (CGAS, GAF, GAPD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

A children's global assessment scale (CGAS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Psychiatric Diagnosis in Child and Adolescent Suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Full publication of results initially presented in abstracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

How can we know whether antidepressants increase suicide risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Suicide risk during antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Pharmaceutical company funding and its consequences: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Do antidepressants precipitate youth suicide?: a nationwide pharmacoepidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Efficacy of antidepressants in juvenile depression: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

National estimates of antidepressant medication use among U.S. children, 1997-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Pharmacotherapy for major depression in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Mirtazapine versus other antidepressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Depressed Adolescents Grown Up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Effects of psychotherapy for depression in children and adolescents: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Treatment options in the management of adolescent depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Ten-year review of rating scales, VII: scales assessing functional impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Considerable variation in NNT - a study based on Monte Carlo simulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

Third-generation antidepressants: do they offer advantages over the SSRIs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

The Risk for Early-Adulthood Anxiety and Depressive Disorders in Adolescents With Anxiety and Depressive Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

Treatment of children with antidepressants: focus on selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

Issues with number needed to treat

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

How have the SSRI antidepressants affected suicide risk?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

The effects of extended evaluation on depressive symptoms in children and adolescents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study1Presented at the American Academy of Child and Adolescent Psychiatry 42nd Annual Meeting, New Orleans, LA, 19 October 19

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

Clinician, Parent, and Child Prediction of Medication or Placebo in Double-Blind Depression Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

Depression in adolescence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

Preliminary studies of the reliability and validity of the children's depression rating scale

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

Suicidal behaviors and childhood-onset depressive disorders: a longitudinal investigation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

The outcome of adolescent depression in the Ontario Child Health Study follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

Pulse clomipramine for depressed adolescents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

Fluvoxamine in the treatment of depressive illness in children and adolescents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

The Maudsley long-term follow-up of child and adolescent depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

The Maudsley long-term follow-up of child and adolescent depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004851.PUB3

7 January 2021

10.1002/14651858.CD004851.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23152227

1 reference

Consolidated OpenCitations Corpus – April 2017